Application for production of letrozole, a 6-class imitative drug of Zhendong pharmaceutical in the treatment of breast cancer

The application of letrozole, a 6-class generic drug declared by Zhendong pharmaceutical, has been accepted Letrozole mainly treats breast cancer The company has declared its API and tablet, mainly to further enrich the company's anti-tumor product line Letrozole is a first-line drug for the treatment of postmenopausal women with advanced breast cancer The original manufacturer of letrozole is Novartis, Switzerland, and it is also a blockbuster product sold worldwide At present, the approved documents in China include Hengrui pharmaceutical and Haizheng pharmaceutical Hengrui medicine is the first one in China Its sales volume in 2012 was nearly 300 million yuan, with a growth rate of more than 30% Yanshu, the leading product of Zhendong pharmaceutical, is mainly used for anti-tumor treatment The company intends to develop a series of drugs around anti-tumor It is understood that in addition to letrozole, a breast cancer drug, in the middle of this month, Zhendong pharmaceutical's prostate cancer treatment drug abiterone acetate applied for clinical acceptance; a class of new drug, lelongtaisu, is also actively preparing to apply for clinical application, similar to docetaxel's violet derivative, which has the characteristics of high efficacy, low drug resistance and small side effects in anti-tumor S-20267, Femara; letrazole; CAS No.: 112809-51-5 molecular formula: c17h11n5 molecular weight: 285.31 molecular structure diagram: letrozole molecular structure appearance White or almost white powder melting point 181-183 ° C